The ORCA-OL data remove a key regulatory risk by demonstrating long-term safety, increasing the probability of NDA approval. With the PDUFA date 32 days away, ACHV is a binary event play. Monitor for any FDA advisory committee meeting announcement or pre-approval inspection updates.
Price Chart
Executive Summary
Achieve Life Sciences presented comprehensive long-term safety data from the ORCA-OL study at ATS 2026, showing cytisinicline maintained a favorable safety profile over 52 weeks of continuous exposure with no new safety signals. The dataset completes the clinical evidence package supporting the NDA, which has a PDUFA date of June 20, 2026. This milestone de-risks the regulatory pathway for a potential first-in-class smoking cessation treatment addressing a large unmet need.
Key Facts
- ORCA-OL study enrolled 475 adults using cigarettes, e-cigarettes, or both, with median 361 days of cytisinicline exposure
- No new safety signals identified by independent Data Safety Monitoring Committee over 52 weeks
- Nausea reported in only 2.5% of participants, consistent with Phase 3 rates
- 94.8% of adverse events were mild or moderate; only 5.7% discontinued due to treatment-related AEs
- NDA accepted for review with PDUFA date of June 20, 2026
- FDA granted Breakthrough Therapy designation and National Priority Voucher for e-cigarette/vaping cessation
Financial Impact
PDUFA catalyst on June 20, 2026; potential market of 25M US adult smokers and 18M e-cigarette users
Risk Factors
- FDA could issue a Complete Response Letter (CRL) on June 20, 2026, especially on CMC or labeling grounds
- Commercial launch execution risk if approved, given cytisinicline is a plant-based alkaloid with manufacturing complexity
- Competition from existing smoking cessation therapies (varenicline, NRT) and potential new entrants
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297888 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 3 | $7.24 $7.19 | ▼ −0.69% | ▼ −0.27% | $6.54 (−9.67%) |
Oct 1, 2026 25d ago | 8-K | $7.24 $7.01 | ▼ −3.18% | ▼ −3.85% | $6.54 (−9.67%) |
Aug 14, 2026 10w ago | 8-K | $7.50 $7.52 | ▼ −0.27% | ▼ −0.94% | $6.54 (+12.80%) |
Aug 11, 2026 10w ago | 8-K | $6.69 $7.25 | ▲ +8.37% | ▲ +7.67% | $6.54 (−2.24%) |
Aug 11, 2026 10w ago | Press Release | $6.77 $6.69 | ▲ +1.18% | ▲ +1.43% | $6.54 (+3.40%) |
Aug 7, 2026 11w ago | Institutional Cluster | $6.65 $6.67 | ▲ +0.30% | ▲ +0.33% | $6.54 (−1.65%) |
Jun 11, 2026 19w ago | Institutional Cluster | $5.52 $5.52 | · 0.00% | ▲ +0.54% | $6.54 (−18.48%) |
Jun 2, 2026 20w ago | 8-K | $5.03 $4.92 | ▼ −2.19% | ▼ −1.49% | $6.54 (+30.02%) |
May 22, 2026 22w ago | EFFECT | $4.69 $4.56 | ▲ +2.77% | ▲ +3.36% | $6.54 (−39.45%) |
May 19, 2026 22w ago | Press Release | $4.45 $4.57 | ▲ +2.70% | ▲ +1.66% | $6.54 (+46.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers